Approaching the Treatment of Hypertriglyceridemia with Confidence
Image For Activity Cover
Expires on Dec 31, 2024
Credit Offered
1 AMA PRA Category 1 Credit
1 ABIM-MOC Point
1 Participation Credit
  • Course Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended

There are multiple challenges that endocrinologists and primary care physicians face when confronting a patient with hypertriglyceridemia. In this session, we will address several of the most pressing questions impacting the acute and chronic management of patients with hypertriglyceridemia.

The session will provide a very brief overview of lipoprotein metabolism, necessary to understand the rationale of interventions, and use a case-based approach to illustrate how current evidence guides us in the management of this serious dysmetabolic condition.

  • Is hypertriglyceridemia a cardiovascular risk factor and, if so, how should we approach it?
  • What pharmacological therapies safely and effectively reduce triglyceride levels?
  • What do we do if we have a patient with a history of pancreatitis and triglyceride levels above 1,000 mg/dL?
  • What novel therapies are emerging for the treatment of severe hypertriglyceridemia?
The intended audience for this activity includes a wide range of health care professionals; many may deem this presentation beneficial.
After participating in this course, learners will be able to:
  1. Identify key steps in lipoprotein metabolism that serve as targets for the treatment of hypertriglyceridemia
  2. Explain the association of high triglycerides with increased cardiovascular risk and pancreatitis
  3. Select safe and effective treatment approaches that decrease triglyceride levels and prevent the development of acute and chronic complications of hypertriglyceridemia using a case-based approach
  4. Appraise current and emerging treatment options in the management of severe hypertriglyceridemia in patients with a history of triglyceride-induced pancreatitis 

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at


L. Maria Belalcazar, MD
Associate Professor, Medicine
Division of Endocrinology and Metabolism
University of Texas Medical Branch Galveston

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported no relevant financial relationships.

The Endocrine Society staff report no relevant financial relationships.
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
Android App Download IOS App Download Powered By